QQ客服 官方微博 反馈留言

	Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
	Lin, Haimin; Han, Dali; Fu, Guobin; Liu, Chengxin; Wang, Lili; Han, Shumei; Liu, Bo; Yu, Jinming
刊名	ONCOTARGETS AND THERAPY
	2019
卷号	12页码:1681-1689
关键词	propensity score matching progression-free survival overall survival
DOI	10.2147/OTT.S193801
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4547732
专题	山东大学
作者单位	Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, 440 Jiyan Rd, Jinan 250117, Shandong, Peopl
推荐引用方式 GB/T 7714	Lin, Haimin,Han, Dali,Fu, Guobin,et al. Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study[J]. ONCOTARGETS AND THERAPY,2019,12:1681-1689.
APA	Lin, Haimin.,Han, Dali.,Fu, Guobin.,Liu, Chengxin.,Wang, Lili.,...&Yu, Jinming.(2019).Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study.ONCOTARGETS AND THERAPY,12,1681-1689.
MLA	Lin, Haimin,et al."Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study".ONCOTARGETS AND THERAPY 12(2019):1681-1689.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。